A recent whole genome sequencing study has revealed hidden insights into the causes of cancer. In an exclusive article, Dr Andrea Degasperi from the Early Cancer Institute at the University of Cambridge, UK spoke to Drug Target Review's Ria Kakkad about the study's implications and the future of whole genome sequencing.
List view / Grid view
4 January 2016 | By Victoria White
Vertex Pharmaceuticals is to use Genomic’s integrated database and state-of-the-art analysis tools to identify target therapeutic pathways...
5 October 2015 | By Victoria White
Biogen will leverage findings from Genomics’ integrated database and analysis tools, which will be used to guide drug research and development...
AstraZeneca joins Genomics England to accelerate the development of new treatments arising from the 100,000 Genomes Project
31 March 2015 | By Victoria White
AstraZeneca has joined with Genomics England to accelerate the development of new diagnostics and treatments arising from the 100,000 Genomes Project...